ft 23 mar 94 survey pharmaceut 1 surviv fastest research use expens never question high cost develop new medicin tighter regulatori demand pressur nation health budget mean group capabl bring innov prepar quickli market surviv flow fund pharmaceut research develop lifeblood drug industri threat drug compani abil rais r amp spend undermin healthcar reform introduc cash strap govern around globe never seen like last year grim nearli everi countri took one rout anoth cut drug expenditur lament mr rene dehecq presid elf sanofi french group last year prescript drug sale top 10 market grew 4 per cent accord im intern market research group sector unlik expand faster year mood industri use growth 17 per cent 20 per cent year descend deep depress climat chang dramat one expans feel great introspect examin constraint explain dr leon rosenberg presid bristol myer squibb pharmaceut research institut admittedli market growth alreadi deceler last year drug compani previous respond cut manufactur market gener administr cost r amp remain inviol precipit rise pharmaceut r amp dollar 5 4bn 1981 dollar 26 5bn last year accord uk base centr medicin research appear end top 10 r amp spender last year increas invest 11 4 per cent deceler r amp growth may inevit accord prof jurgen drew presid intern r amp roch swiss healthcar group industri clearli spend global prescript sale would need reach dollar 280bn year within 10 year justifi present level invest chanc reach figur low non exist warn prof drew 10 largest prescript drug market repres 90 per cent world market worth dollar 114 9bn last year dr rosenberg conclud worst case scenario would pharmaceut industri know disappear compani longer believ likelihood gener reason return money put research headi day r amp impact healthcar reform consequ slow sale growth r amp spend seen tabl see page two compil financi time group mostli european compani strong volum growth manag avoid slow invest exampl sweden astra three british compani glaxo wellcom smithklin beecham increas spend 20 per cent last year compani regist singl digit r amp growth first time recent memori actual cut r amp spend last year among top 40 odd pharmaceut group five compani three us one europ one japan forc reduc expenditur real also nomin term mr lodewijk de vink presid chief oper offic warner lambert whose drug subsidiari park davi cut budget explain r amp use cost centr never question day macho spend current level spend clearli unsustain compani cut r amp necessarili better danger cut research develop consider howev group could prove termin compani start cut r amp lifeblood pharmaceut compani warn dr edward scolnick presid merck research laboratori us biggest drug group mr bill steer chairman chief execut pfizer us chairman us pharmaceut manufactur associ explain compani without anyth pipelin slow sale go find increasingli difficult justifi fund r amp aggress go get frighten incom reced set kind synergist death spiral cut r amp incom drop kill ironi time r amp spend growth deceler scientif opportun creat innov new medicin expand rapidli biotechnolog greater understand life death cell open vast new scientif medic horizon accord sir richard syke chief execut glaxo europ largest drug group basic biolog cellular mechan becom understood drug design becom scienc art say dr william scott senior vice presid exploratori drug discoveri research bristol myer squibb explain opportun make better drug greater ever short period time gene human bodi sequenc identifi molecular basi diseas begin treat problem access new technolog exercis mind research director mani clearli irk view propag small biotechnolog pharmaceut group left behind although group roch rhone poulenc rorer acquir biotechnolog compani other limit small joint ventur adopt portfolio approach difficulti pharmaceut compani creat hous expertis capabl judg project pick dr hiroyki nagasako board director corpor plan daiichi japanes group explain compani plan link biotechnolog compani excit thing happen us biotechnolog industri frankli need develop proper level expertis manag technolog unfortun skill expens busi wast lot money given increasingli difficult environ pharmaceut compani capabl discov rapidli develop innov drug global basi surviv dr john mccall execut director discoveri research upjohn us say right respons new environ clearli develop novel compound fun work easier regist regulatori author profit place copi cat drug futur target innov drug high risk high reward strategi develop go riskier say dr robert spiegel senior vice presid clinic research schere plough research institut us compani capabl discov innov profit compound allow fund research other go go tube meanwhil given deterior oper environ compani board insist money spent r amp invest increasingli product dr trevor jone wellcom director research develop medic uk admit recent pressur look hard ought simpli almost r amp director focus effort cut number therapeut area explor also concentr resourc take fewer innov compound laboratori clinic trial aim develop drug quickli possibl three main market us japan europ huge cost develop medicin recoup regulatori environ conduc rapid develop howev regulatori author requir simpl data prove drug safe effect alreadi demand data demonstr new compound better exist therapi addit pharmaceut compani also drawn statist methodolog quagmir health econom author demand data prove medicin cost effect trend add time cost durat drug develop given increas cost drug develop need focu resourc number pharmaceut compani react forg allianc particular therapeut categori need collabor compet basic research explain mr robert cawthorn chief execut rhone poulenc rorer howev greater scientif collabor cost cut better use exist resourc go far go lot smaller industri go lot consolid say mr steer pfizer second tier compani need alloc resourc care employ consider skill enjoy great deal luck develop next gener product capabl ensur surviv ever harshen healthcar environ stake involv play molecular roulett higher ever fail develop innov drug independ end decad pharmaceut research develop 1992 93 r amp 1992 r amp 1993 increas sale r amp dollarsm dollarsm 1993 1993 sale 1 roch 1 090 gt 1 240 gt 13 8 5 261 23 56 2 johnson amp johnson 1 111 1 200 8 0 14 130 8 5 3 merck 1 117 1 170 4 7 10 490 11 15 4 glaxo 880 1 093 24 2 6 060 18 00 5 bm 932 972 4 3 6 524 14 90 6 eli lilli 925 954 3 1 6 500 14 67 7 pfizer 763 888 16 4 6 210 14 30 8 abbott 772 881 14 1 8400 10 48 9 bayer 714 810 13 4 5 522 14 60 10 sandoz 751 gt 801 gt 6 7 4 948 gt 16 2 11 hoechst 792 n n n n 12 smithklin beecham 609 732 20 2 5 153 14 20 13 american home product 552 663 20 1 8 304 7 98 14 ciba 657 n n n n 15 monsanto 651 620 4 8 7 902 7 80 16 american cyanamid 531 596 12 2 4 277 13 9 17 schere plough 521 578 10 9 4 341 13 30 18 rhone poulenc rorer 521 561 7 7 4 000 14 05 19 upjohn 510 566 11 0 3 007 18 80 20 takeda 535 557 4 1 6 720 8 28 21 boehring ingelheim 489 n n n n 22 wellcom 369 482 30 6 3 019 15 90 23 corang 459 n n n n 24 marion merrel dow 465 451 3 0 2 818 16 0 25 schere 422 450 6 6 2 379 18 90 26 zeneca 378 429 13 5 2 768 15 49 27 elf sanofi 352 414 17 6 2 120 19 60 28 syntex 374 404 8 0 2 123 19 00 29 astra 298 389 30 5 2 712 14 30 30 pharmacia 384 n n 3 290 n 31 park davi 383 380 0 8 2 114 18 00 32 yamanouchi 320 360 12 5 n n 33 fujisawa 335 357 6 6 2 390 14 80 34 sankyo 318 345 8 5 3 570 9 60 35 genetech 279 299 7 2 457 65 00 36 eisai 273 277 1 5 2 100 13 20 37 novo nordisk 225 257 14 2 1 790 14 30 38 shionogi 260 254 2 3 2 140 11 80 39 daiichi 217 234 7 8 1 880 12 30 40 e merck 217 221 1 8 1 572 14 06 41 knoll basf 172 185 7 6 1 050 17 60 42 synthelabo 156 174 11 5 1 114 15 60 43 solway 180 n n n n 44 are serono 133 118 11 3 755 15 60 currenc decemb 31 1993 indic group year end june 30 1993 indic healthcar estim 1993 indic year end august 30 1993 sourc financi time data compil ann brit dullforc paul abraham